This moderately potent steroid-based cream is especially appropriate for moist and/or weeping lesions caused by moderate atopic eczema. The low concentration of Betamethasone makes it perfect for sensible areas like the face and flexures.

Betnovate RD is formulated with an active ingredient named betamethasone valerate. This compound is part of the steroid family, known for diminishing inflammation and discomfort.

The "RD" in its name indicates "Ready Diluted," signifying its lower concentration of the active ingredient compared to Audavate or Betnovate. This makes it suitable: • for less severe atopic eczema, or • to maintain the condition of the skin once Audavate/Betnovate has improved the symptoms.

Key features:

• Designed for moist and/or weeping skin caused by moderate atopic eczema;
• Indicated for adults, elderly and children over 1 year.
• Suitable for delicate areas such as the face and flexures;
• Prescription-strength accessible after a consultation with our pharmacist.

Frequently Asked Questions (FAQs):

Is this an over-the-counter medication?

No, this is a prescription-only medication that can be purchased over the counter via a private service called PGD (Patient Group Direction).

What condition can I treat with this?

Due to restrictions on the PGD, we can only supply this medication to treat Moderate to Severe Atopic Eczema.

What will happen once I have answered the questions in the form?

A pharmacist trained to provide this private service will assess the form and call you to discuss the answers you provided with you.

Why do I need to provide my phone number?

In order to dispense this medication without a prescription, the consultation must be carried out via phone or video call. As well as this being a legal requirement to ensure that the medication is suitable for you, the final phone consultation will allow you to ask any questions you may have to the pharmacist.

Is the consultation private?

Patient confidentiality is one of our top priorities, both the form you fill and the phone consultation are strictly confidential between you and the pharmacist.

Do I need to pay for the consultation?

The price you see is inclusive of the consultation fee, so you will not have to pay anything extra.

Please read the patient information leaflet before starting the treatment.

Active ingredient: Betamethasone Valerate B.P. Equivalent to Betamethasone 0.025%.

Excipients with known effect: Chlorocresol, Cetostearyl alcohol

Apply a thin layer to the affected area, rubbing in and allowing time for absorption before using an emollient. Use once or twice daily for up to 2 weeks (5 days if treating a delicate area eg. face, flexures), then adjust the frequency, switch to a milder treatment or review with your doctor.

The maximum treatment length on delicate areas such as the face and flexures should last only 5 days.

Keep all medicines out of the reach and sight of children.

Do not store above 30 °C.

Once opened, do not use this medicine for more than 3 months.

Do not use Betnovate RD after the expiry date which is shown on the tube or carton. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required. This will help to protect the environment.

Avoid smoking or approaching open flames because of the significant burn risk. Materials, including clothing, bedding, and dressings, which have come in contact with this product, are more prone to catching fire, posing a severe fire threat. While washing these items might lessen the residue of the product, it might not entirely eliminate it.

Discontinue Betnovate RD and inform your doctor immediately if:

• You notice a widespread skin rash.
• Your skin condition deteriorates, becomes inflamed, or appears swollen, suggesting an allergy to the product, an infection, or the need for a different treatment.
• If you have psoriasis, you might observe pus-filled bumps beneath the skin, a rare condition called pustular psoriasis, which can emerge during or post-treatment.